| Title |
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, June 2021
|
| DOI | 10.1158/1535-7163.mct-21-0221 |
| Pubmed ID | |
| Authors |
Brion W. Murray, Dayong Zhai, Wei Deng, Xin Zhang, Jane Ung, Vivian Nguyen, Han Zhang, Maria Barrera, Ana Parra, Jessica Cowell, Dong J. Lee, Herve Aloysius, Evan Rogers |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 33% |
| France | 2 | 13% |
| Italy | 2 | 13% |
| Colombia | 1 | 7% |
| Mexico | 1 | 7% |
| Unknown | 4 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 60% |
| Scientists | 4 | 27% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
| Science communicators (journalists, bloggers, editors) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 31% |
| Other | 2 | 7% |
| Student > Bachelor | 2 | 7% |
| Student > Doctoral Student | 1 | 3% |
| Student > Ph. D. Student | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 13 | 45% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 5 | 17% |
| Medicine and Dentistry | 4 | 14% |
| Nursing and Health Professions | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 16 | 55% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2023.
All research outputs
#3,153,374
of 24,716,872 outputs
Outputs from Molecular Cancer Therapeutics
#435
of 4,004 outputs
Outputs of similar age
#73,712
of 435,154 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#3
of 52 outputs
Altmetric has tracked 24,716,872 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,004 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,154 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.